Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cibus (CBUS)
NASDAQ:CBUS
CBUS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.17 - $23.18
Previous CloseN/A
Volume64.89K
Average Volume (3M)146.15K
Market Cap
$88.50M
Enterprise Value$288.77M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Mar 20, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.48
Shares Outstanding30,795,582
10 Day Avg. Volume130,366
30 Day Avg. Volume146,145
Standard Deviation0.39
R-Squared0.06
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.55
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market Cap3.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit203.08
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$11.00Price Target Upside409.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Cibus News
PremiumCompany Announcements
Cibus Enhances Board with Appointment of August Moretti
PremiumCompany Announcements
Cibus Reports Strategic Shift and Financial Update---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceCibus reported Q3/24 revenues of $1.7M, which beat consensus by ~143%, driven by collaboration agreements for Soybean contract research.
Market OpportunityThe company plans to get its Soybean platform operational by end of 2024, opening up another large market that could be as large as 125M acres.
Technological AdvancementsThe 'transformative' nature of Cibus' trait machine gene editing process offers a significant competitive advantage, with higher conversion ratios compared to other techniques like Crispr.
Bears Say
Dilution EffectFollowing the announcement of the equity raise, the model was adjusted to reflect the dilution effect of the revised share count.
Financial ChallengesCibus reported a net loss of ~$202M, primarily due to a ~$181M goodwill impairment charge during the quarter.
Regulatory And Execution RisksRisks include dilution risk, execution risk, regulatory risk, demand risk, technology risk, competition risk, and uncertainty related to macroeconomic conditions and geopolitical environment.
---
Ownership Overview
27.84% Insiders
10.98% Mutual Funds
4.82% Other Institutional Investors
51.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CBUS FAQ
What was Cibus’s price range in the past 12 months?
Cibus lowest stock price was $2.17 and its highest was $23.18 in the past 12 months.
What is Cibus’s market cap?
Cibus’s market cap is $88.50M.
When is Cibus’s upcoming earnings report date?
Cibus’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were Cibus’s earnings last quarter?
Cibus released its earnings results on Nov 07, 2024. The company reported -$7.63 earnings per share for the quarter, missing the consensus estimate of -$0.873 by -$6.757.
Is Cibus overvalued?
According to Wall Street analysts Cibus’s price is currently Undervalued.
Does Cibus pay dividends?
Cibus does not currently pay dividends.
What is Cibus’s EPS estimate?
Cibus’s EPS estimate is -0.68.
How many shares outstanding does Cibus have?
Cibus has 30,795,582 shares outstanding.
What happened to Cibus’s price movement after its last earnings report?
Cibus reported an EPS of -$7.63 in its last earnings report, missing expectations of -$0.873. Following the earnings report the stock price went up 20%.
Which hedge fund is a major shareholder of Cibus?
Currently, no hedge funds are holding shares in CBUS
---
Cibus Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (409.26% Upside)
$11.00 (409.26% Upside)
Blogger Sentiment
Bullish
CBUS Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $24.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.04%
12-Months-Change
Fundamentals
Return on Equity
-155.86%
Trailing 12-Months
Asset Growth
-53.80%
Trailing 12-Months
Company Description
Cibus
Calyxt, Inc. operates as a healthy food ingredient company. It engages in the development of crops by leveraging processes that occur in nature, combining its gene-editing technology and technical expertise with its commercial strategy to bring healthier ingredients to the market. The company was founded by Daniel F. Voytas and André Choulika on January 8, 2010 and is headquartered in Roseville, MN.
---
CBUS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call revealed significant progress in Cibus's transformation to a commercial gene editing company, with successful trait developments and strategic collaborations. However, financial challenges persist with increased net losses, and there are ongoing regulatory and commercialization hurdles.Read More>---
CBUS Stock 12 Month Forecast
Average Price Target
$11.00
▲(409.26% Upside)
Technical Analysis
Codexis
―
FMC
―
Intellia Therapeutics
―
Bioceres Crop Solutions
―
Ginkgo Bioworks Holdings
―
Best Analysts Covering CBUS
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-43.66%
reiterated a buy rating 4 days ago
Copying Austin Moeller's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -43.66% per trade.
---